3 Medicare Rules All Retirees Need to Know in 2026

Medicare costs and enrollment rules for 2026 include a standard Part B premium of $202.90 (up from $185 in 2025) and a Part B deductible of $283 (up from $257); Part A inpatient deductible is $1,736 and post‑60‑day hospital coinsurance is $434, while skilled nursing facility daily coinsurance is $217. Timely enrollment — a seven‑month initial window around age 65 or a special window if covered by a qualifying employer plan (20+ employees) — avoids lifetime surcharges on Part B and Part D; COBRA does not qualify. Medigap (supplemental) policies, sold by private insurers, pair with original Medicare and are best obtained during a six‑month open enrollment beginning when one is 65 and enrolled in Part B, otherwise insurers can deny coverage or raise premiums based on preexisting conditions.

Analysis

Market structure: Rising Part B and deductible levels (Part B premium +9.6% YoY to $202.90; Part A inpatient deductible +3.6% to $1,736) creates predictable incremental demand for private Medicare products (Medicare Advantage, Medigap). Direct beneficiaries are large insurers with MA/Medigap scale (UnitedHealth UNH, Humana HUM, CVS/Caremark CVS, Cigna CI, Centene CNC) who can price risk and grow membership; hospitals and small regional providers face slower pricing power. On cross-assets, expect defensive equity bid into insurers, modest upward pressure on long-term Treasury yields over years as entitlement spending edges higher, and slightly higher implied vol on insurer names around enrollment windows and CMS rule announcements.

Risk assessment: Tail risks include major policy shifts (Congress expanding Medicare negotiation or cutting MA benchmarks >2% could reverse margins) and acute medical-cost inflation driving loss ratios above guidance (>1–2 points). Immediate (0–30 days) risk: enrollment-season operational glitches; short-term (3–6 months): rate renewals and Q2 earnings; long-term (1–5 years): demographic-driven cost growth and regulatory clampdowns. Hidden dependencies: employer-sponsored coverage rules (COBRA/non-COBRA) materially change special enrollment flows; PBM contractual passthroughs affect net margins.

Trade implications: Direct plays: overweight large MA/Medigap insurers (UNH/HUM) and underweight fee-for-service reliant hospitals (HCA) for a 3–12 month horizon. Pair trade: long CNC (underpriced MA expansion) vs short HCA (margin pressure) over 3–9 months. Options: buy 6–9 month call spreads on UNH or HUM to capture enrollment tailwinds while capping risk; sell short-dated calls to enhance yield if assigned premium >2%/month.

Contrarian angles: Consensus underestimates Medigap re‑pricing power during guaranteed-issue windows — early enrollment surges can lift revenues with low acquisition cost; conversely, market may overreact to single-year premium upticks (2026 Part B +9.6%) as noise rather than structural shift. Historical analog: post-ACA surge in MA enrollment rewarded scale players; similar dynamics could repeat absent regulatory shocks. Unintended consequence: aggressive insurer pricing could invite legislative pushback; position sizing should limit political tail risk.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in UnitedHealth (UNH) within 30 days to capture Medicare Advantage and Medigap scale; target 12–18% upside over 6–12 months, set stop-loss at -8%.
• Add a 1–2% long position in Humana (HUM) for concentrated Medicare exposure; consider trimming if HCR/legislative signals indicate MA benchmark cuts >2% (close within 5 trading days).
• Implement a pair trade: go 2% long Centene (CNC) vs 1.5% short HCA Healthcare (HCA) for 3–9 months to play MA share gains vs fee-for-service margin pressure; exit if CNC underperforms peers by >10% in 60 days.
• Buy a 6–9 month UNH 520/570 call spread (size 0.5–1% of portfolio) to asymmetrically benefit from enrollment tailwinds while capping capital at premium paid.
• Monitor (and act on) two triggers: 1) CMS publishes MA enrollment growth <+3% YoY (reassess long positions within 10 trading days); 2) any Congressional bill proposing >2% MA payment reduction advances out of committee (reduce insurer exposure by 50% within 5 trading days).